Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study

doi:10.4240/wjgs.v15.i7.1340

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 7

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2789)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

WORD

HTML

1312

Figures (1-3)

204

Tables (1-5)

213

Sum=1826

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

190

Download

647

Sum=837

Jul 27, 2023 (publication date) through Jan 27, 2025

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastrointest Surg. Jul 27, 2023; 15(7): 1340-1353
Published online Jul 27, 2023. doi: 10.4240/wjgs.v15.i7.1340

Table 2 Pretransplant treatments, n (%)

	Before PSM			After PSM
	HCC (n = 141)	cHCC-CC (n = 111)	P value	HCC (n = 70)	cHCC-CC (n = 70)	P value
Locoregional therapy prior to LT	112 (79.4)	74 (66.7)	0.03	50 (71.4)	52 (74.3)	0.849
TACE	102 (72.3)	65 (58.6)	0.023	45 (64.3)	46 (65.7)	0.859
Liver resection	24 (17.0)	20 (18.0)	0.868	10 (14.3)	14 (20.0)	0.502
RFA	46 (32.6)	17 (15.3)	0.002	17 (24.3)	12 (17.1)	0.404
Radiation therapy	13 (9.2)	8 (7.2)	0.65	6 (8.6)	6 (8.6)	0.618
Number of locoregional therapies before LT > 3	56 (39.7)	34 (30.6)	0.147	27 (38.6)	26 (37.1)	0.862
AFP > 20 ng/mL	37 (26.2)	56 (50.5)	< 0.001	23 (32.9)	25 (35.7)	0.859
PIVKA-II > 40 mAU/mL	50 (35.5)	40 (39.2)	0.591	30 (42.9)	19 (30.2)	0.152

LT: Liver transplantation; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation; AFP: Alpha-fetoprotein; PIVKA-II prothrombin-induced by vitamin K absence-II; HCC: Hepatocellular carcinoma; PSM: Propensity score matching; cHCC-CC: Combined hepatocellular carcinoma and cholangiocarcinoma.

Citation: Kim J, Joo DJ, Hwang S, Lee JM, Ryu JH, Nah YW, Kim DS, Kim DJ, You YK, Yu HC. Liver transplantation for combined hepatocellular carcinoma and cholangiocarcinoma: A multicenter study. World J Gastrointest Surg 2023; 15(7): 1340-1353
URL: https://www.wjgnet.com/1948-9366/full/v15/i7/1340.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i7.1340